The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.

The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.

Date of Patent:
Nov. 28, 2017

Filed:

Sep. 11, 2013
Applicant:

Industry-university Cooperation Foundation Hanyang University, Seoul, KR;

Inventors:

Eun Jung Baek, Seoul, KR;

Eun Mi Lee, Gyeonggi-do, KR;

Attorney:
Primary Examiner:
Int. Cl.
CPC ...
A61K 38/17 (2006.01); C12N 5/078 (2010.01); C12N 5/0787 (2010.01); A61K 35/15 (2015.01); A61K 35/18 (2015.01);
U.S. Cl.
CPC ...
C12N 5/0641 (2013.01); A61K 35/15 (2013.01); A61K 35/18 (2013.01); A61K 38/1709 (2013.01); C12N 5/0642 (2013.01); C12N 2500/99 (2013.01); C12N 2501/125 (2013.01); C12N 2501/14 (2013.01); C12N 2501/2303 (2013.01); C12N 2501/48 (2013.01); C12N 2501/998 (2013.01); C12N 2506/025 (2013.01); C12N 2506/11 (2013.01);
Abstract

The present invention relates to the in vitro production of erythrocytes/granulocytes and to the treatment of myelodysplastic syndrome using a method for inducing hemoblast differentiation. The present invention provides a media composition comprising gelsolin as an active ingredient for inducing the differentiation of hematopoietic precursor cells into erythrocytes/granulocytes, and a pharmaceutical composition comprising gelsolin as an active ingredient for treating myelodysplastic syndrome. Since the composition of the present invention improves the efficiency of differentiation of hematopoietic precursor cells into erythrocytes/granulocytes while maintaining a low rate of occurrence of cell dysplasia and having the effect of improving the enucleation rate and cell survivability, the present invention can be effectively used for producing erythrocytes/granulocytes in vitro and for treating myelodysplastic syndrome.


Find Patent Forward Citations

Loading…